201422-04-0 (L-Leucine,N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-alanyl-,L-Leucine,N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-alanyl-)

CAS号:
201422-04-0
中文名称:
L-Leucine,N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-alanyl-
英文名称:
L-Leucine,N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-alanyl-
分子式:
C78H142N22O20
分子量:
1708.0974984169
简介:
Autocamtide-2-related inhibitory peptide, myristoylated 是Autocamtide-2-related inhibitory peptide 烷基化修饰后的形式。 Autocamtide-2-related inhibitory peptide 是高度特异性的、CaMKII 的有效抑制剂,其IC50 值为 40 nM。

L-Leucine,N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-alanyl-(201422-04-0)名称与标识符

名称

中文别名:
H-LYS(MYR)-LYS-ALA-LEU-ARG-ARG-GLN-GLU-ALA-VAL-ASP-ALA-LEU-OH;KL-13;
英文别名:
L-Leucine, N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-α-glutamyl-L-alanyl-L-valyl-L-α-aspartyl-L-alanyl-;m-AIP;Autocamtide-2-related inhibitory peptide, myristoylated;AKOS027470324;Autocamtide-2-related inhibitory peptide, myristoylated TFA;L-Leucine,N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-alanyl-;DA-50813;201422-04-0;PD080280;

标识符

InChIKey:
QKOOKZWMKXOQRL-YJDHHEDVSA-N
Inchi:
1S/C78H142N22O20/c1-11-12-13-14-15-16-17-18-19-20-21-32-60(102)86-38-25-23-28-50(80)67(110)92-51(29-22-24-37-79)68(111)89-47(8)64(107)97-56(41-44(2)3)74(117)94-53(31-27-40-88-78(84)85)70(113)93-52(30-26-39-87-77(82)83)71(114)95-54(33-35-59(81)101)72(115)96-55(34-36-61(103)104)69(112)90-49(10)66(109)100-63(46(6)7)75(118)98-57(43-62(105)106)73(116)91-48(9)65(108)99-58(76(119)120)42-45(4)5/h44-58,63H,11-43,79-80H2,1-10H3,(H2,81,101)(H,86,102)(H,89,111)(H,90,112)(H,91,116)(H,92,110)(H,93,113)(H,94,117)(H,95,114)(H,96,115)(H,97,107)(H,98,118)(H,99,108)(H,100,109)(H,103,104)(H,105,106)(H,119,120)(H4,82,83,87)(H4,84,85,88)/t47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,63-/m0/s1
SMILES:
O=C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)N([H])[H])=O)=O)=O)N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@@]([H])(C([H])([H])[H])C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@@]([H])(C([H])([H])[H])C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)=O)C([H])([H])C(=O)O[H])=O)C([H])(C([H])([H])[H])C([H])([H])[H])=O)=O)C([H])([H])C([H])([H])C(=O)O[H])=O)C([H])([H])C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H]

L-Leucine,N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-alanyl-(201422-04-0)物化性质

计算特性

  • 精确分子量 : 1707.07707501g/mol
  • 氢键供体数量 : 23
  • 氢键受体数量 : 24
  • 可旋转化学键数量 : 67
  • 同位素质量 : 1707.07707501g/mol
  • 重原子数量 : 120
  • 复杂度 : 3340
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 13
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : -3.6
  • 拓扑分子极性表面积 : 714Ų

L-Leucine,N2-(1-oxotetradecyl)-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-arginyl-L-arginyl-L-glutaminyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-alanyl-(201422-04-0)推荐厂家 更多厂家(10)